Status:
UNKNOWN
Topical Tranexamic Acid After Intravitreal Injections
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Subconjunctival Hemorrhage
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
We aim to investigate whether topical administration of Tranexamic acid can reduce the occurence of subconjunctival hemorrahge after routine intravitreal injections for retinal conditions.
Eligibility Criteria
Inclusion
- Subjects receiving intravitreal injections as part of their routine ophthalmological care
Exclusion
- Pregnancy, Oral contraceptives/HRT use, Known systemic autoimmune disease, Renal failure, active/suspected infection or inflammation in the treated eye, subconjunctival hemorrahge prior to inclusion, History of subarachnoid hemorrahge, thromboembolic events, increased risk for thromboembolic events, known sensitivity to the study drug
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04400916
Start Date
September 1 2020
End Date
December 1 2021
Last Update
May 26 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.